This series provides timely information about the implementation of recently approved lenacapavir as pre-exposure prophylaxis (PrEP) to reduce the risk of acquiring HIV-1. The series will cover how lenacapavir as PrEP is implemented in practice at the clinical, patient, and organizational levels. Faculty throughout the series discuss how different provider types — clinicians, patient navigators, and pharmacists — within various settings can implement this first-of-its-kind biomedical intervention.
As HIV prevention evolves, long-acting injectable options like lenacapavir are emerging as promising tools to expand access and adherence. Effective implementation of new interventions calls for thoughtful planning across key areas, including operations, staffing, finance, and patient access.
This webinar covers patient navigation touchpoints along the PrEP continuum for injectable lenacapavir, patient education strategies, expanding the capacity of PrEP navigation staff to implement injectable PrEP, and future opportunities for expanded implementation in mobile health settings.
In the first webinar of the series, faculty – including principal investigators from the PURPOSE trials – review clinical data and delve into opportunities and challenges for the real-world implementation of lenacapavir as PrEP.
This webinar covers medication administration, managing side effects, potential drug interactions, and transitioning patients on or off lenacapavir as PrEP.